Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease - Runeberg-Roos, Pia; Piccinini, Elisa; Penttinen, Anna-Maija; Mätlik, Kert; Heikkinen, Hanna; Kuure, Satu; Bespalov, Maxim M.; Peränen, Johan; Garea-Rodríguez, Enrique; Fuchs, Eberhard; Airavaara, Mikko; Kalkkinen, Nisse; et al. (Neurobiology of disease, 2016)
Keywords: Amphetamine - pharmacology; Animals; CHO Cells; Cricetulus; Disease Models, Animal; Drug Design; GDNF; Genetic Variation - genetics; GFRα1; GFRα2; Growth factor; Heparan sulfate; Heparin; Humans; Macaca fascicularis; Male; Models, Molecular; Neurology; Neurturin; Neurturin - chemistry; Neurturin - genetics; Neurturin - metabolism; NRTN; Oxidopamine - toxicity; Parkinson Disease - complications; Parkinson Disease - drug therapy; Parkinson Disease - etiology; Parkinson Disease - metabolism; Parkinson's disease; Proto-Oncogene Proteins c-ret - genetics; Proto-Oncogene Proteins c-ret - metabolism; Rats; Rats, Wistar; RET; Stereotyped Behavior - drug effects; Sympatholytics - toxicity; Tyrosine 3-Monooxygenase - metabolism; RET; Heparan sulfate; Parkinson's disease; IHC; IP; SNpc; Neurturin; pgsA 745 cells; WB; N1–4; P-TYR; OHDA; GDNF; PD; TH; GFRα1; NRTN; MPTP; Heparin; NV1–4; GAPDH; GFRα2; Growth factor; untagged NRTN variants; Glial cell line-Derived Neurotrophic Factor; Western blotting; phosphotyrosine; heparin; GDNF family receptor α2; hydroxydopamine; GDNF family receptor α1; immunoprecipitated; V5-tagged NRTN variants N1–4; Rearranged during Transfection (a transmembrane tyrosine kinase receptor); immunohistochemical; tyrosine hydroxylase; growth factor; substantia nigra pars compacta; heparan sulfate; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; CHO cells deficient in heparan sulfate from ATCC; neurturin; glyceraldehyde 3-phosphate dehydrogenase